IL2 and melanoma: reported a case of advanced melanoma with acquired resistance to multiple systemic agents, including ipilimumab, IL-2, and pembrolizumab, that subsequently had a complete response following GRID SFRT and pembrolizumab, suggesting combination therapy may re-sensitive patients to treatment (41).